Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Francis Collins

NIH Director Addresses Gathering of Experts on Autoimmune Diseases

Richard Quinn  |  November 10, 2015

NIH Director Francis Collins, MD, PhD, is working to improve funding for research into new treatments for lupus and RA through the Accelerating Medicines Partnership, a coalition of private and public partners identifying and validating promising biological targets for therapeutics…

Filed under:ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus

Rheum After 5: Introducing Dr. Grayson & the Affordable Rock ‘n’ Roll Act

Carol Patton  |  January 19, 2021

Peter Grayson, MD, MSc, a tenure track investigator at the National Institutes of Health (NIH) Intramural Research Program, Bethesda, Md., sometimes wonders how his life would have turned out if the band he was playing in during college had signed a recording contract with a major record label. Dr. Grayson has been playing the piano…

Filed under:AudioProfilesRheum After 5 Tagged with:Dr. Peter Grayson

Rheumatology Research Foundation & NIH Program Bears Fruit

From the College  |  April 26, 2018

The Rheumatology Research Foundation has been actively involved with the NIH’s Accelerating Medicines Partnership for Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) program, launched in 2014 as a public–private partnership to spur development of new therapeutic options for RA and lupus. Recently, the NIH released new datasets that will help clinical investigators accelerate therapies…

Filed under:From the CollegeResearch Rheum Tagged with:LupusRheumatoid arthritisRheumatology Research FoundationSystemic lupus erythematosus

Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network

Lara C. Pullen, PhD  |  October 17, 2017

CHICAGO—“Why do so many drugs fail in clinical trials?” asked Michael Brenner, MD, chief of rheumatology, immunology and allergy at Brigham and Women’s Hospital in Boston. This question, previously posed by Francis Collins, MD, PhD, director of the National Institutes of Health, prompted a discussion among scientists and stakeholders in the pharmaceutical industry. The conversation…

Filed under:ConditionsMeeting ReportsResearch RheumRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:Accelerating Medicines PartnershipFederation of Clinical Immunology SocietiesFOCIS 2017Lupusmeeting reportsRAResearchRheumatic DiseaseRheumatoid arthritisrheumatologysingle-cell disease"SLESystemic lupus erythematosusTreatment

AMP RA/Lupus Network Shares Its Progress

Lara C. Pullen, PhD  |  September 26, 2017

Researchers from the AMP RA/Lupus Network came together in June at the annual FOCIS meeting to share their progress as they perform a systematic molecular deconstruction of human diseases…

Filed under:ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:Accelerating Medicines PartnershipLupusNational Institutes of Health (NIH)Rheumatoid Arthritis (RA)systemic lupus erythematosus (SLE)

Accelerating Medicines Partnership Advances Research for Autoimmune Diseases

Richard Quinn  |  November 11, 2016

Advancing the understanding of autoimmune diseases has implications for precision medicine, according to Robert Carter, MD, of the NIH. Research funded through the NIH’s Accelerating Medicines Partnership has the potential to develop better biomarkers and clinical trials for lupus and RA, paving the way for more personalized treatment…

Filed under:Career DevelopmentProfessional TopicsResearch Rheum Tagged with:Accelerating Medicines Partnershipfederal fundingFundingLupusNational Institutes of Health (NIH)ResearchRheumatoid Arthritis (RA)systemic lupus erythematosus (SLE)

White House Proposes Measures to Speed Genomic Test Development

Toni Clarke  |  July 7, 2016

WASHINGTON (Reuters)—The White House announced on Wednesday measures aimed at advancing President Barack Obama’s precision medicine initiative, including plans to speed the development of tests used to identify genetic mutations and guide medical treatment. The U.S. Food and Drug Administration said it planned to issue a proposal to create performance standards to guide development of…

Filed under:Legislation & AdvocacyProfessional Topics

Knowledge of Genetic Risk Doesn’t Prompt Behavior Changes

Kathryn Doyle  |  March 23, 2016

(Reuters Health)—Telling patients about their genetic risk for disease doesn’t usually lead to healthy behavior changes, such as eating better or exercising more, according to a new analysis of existing studies. Researchers selected 18 studies that tracked seven potential behavior changes—such as quitting smoking, diet, physical activity and using sun protection—among people who had received…

Filed under:Conditions Tagged with:behaviorbehavior changegenetic riskgenetic testPatients

Verily, Vanderbilt to Test Enrollment in U.S. Precision Medicine Pilot

Reuters Staff  |  February 25, 2016

(Reuters)—The National Institutes of Health on Thursday named Verily, formerly Google Life Sciences, as advisor to Nashville’s Vanderbilt University in a pilot program to launch the Precision Medicine Initiative outlined by President Barack Obama last year. The program aims to enroll 79,000 volunteer participants by the end of this year to supply personal data that…

Filed under:Professional Topics Tagged with:National Institutes of Health (NIH)NIHPrecision Medicine Initiativestudy

U.S. NIH Drug Facility Suspended after Contamination Found

Bill Berkrot  |  June 7, 2015

(Reuters)—The National Institutes of Health said on Thursday it had suspended operations of a facility that makes products used for clinical research after the discovery of fungal contamination in two vials of albumin. Vials made from the same batch of albumin had been administered to six patients, though it is not known if those were…

Filed under:Drug Updates Tagged with:AlbuminDrug SafetyFood and Drug AdministrationNational Institutes of Health (NIH)

  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences